When It Comes to the Treatment of Infantile Spasms

Time to treatment initiation and effective dosing can have a significant and lasting impact

Pyros Pharmaceuticals™ is developing enhanced specialty pharmaceuticals for rare diseases

At Pyros, we're focused on setting a new standard in healthcare, starting with patients suffering from infantile spasms. We're taking this opportunity to lift up families and support them in treating this severe, rare disease.

Michael Smith

Chief Executive Officer

June 17, 2024

Pyros Pharmaceuticals Announces FDA Approval of VIGAFYDE™ (vigabatrin) as the First and Only Ready-to-Use Vigabatrin Oral Solution

Read more